Literature DB >> 7623967

Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration.

S B Auerbach1, J F Lundberg, S Hjorth.   

Abstract

The inhibition of serotonin (5-HT) release produced by antidepressants varying in relative selectivity for blocking uptake of 5-HT and noradrenaline (NA) was compared. Release was measured by microdialysis in anesthetized rats with nerve terminal 5-HT uptake inhibited by local infusion of citalopram (1 microM) through a dialysis probe in hippocampus. With 5-HT uptake first blocked in hippocampus, systemic injection of uptake inhibitors produced decreases in dialysate 5-HT, presumably due to autoreceptor stimulation in the raphe. The largest decreases (about 60-70%) in 5-HT were produced by the selective 5-HT uptake inhibitors sertraline, paroxetine and citalopram. Nonselective blockers caused less suppression of release. Thus, the maximum decrease in 5-HT was 35% after clomipramine, a less selective 5-HT uptake inhibitor, and < or = 30% after the nonselective 5-HT/NA uptake blockers imipramine and amitriptyline, 5-HT was not decreased after maprotiline, a selective NA uptake blocker. Pretreatment with (+)WAY100135 to block 5-HT1A autoreceptors, abolished the inhibition of 5-HT release produced by systemic sertraline, clomipramine and imipramine. One explanation for the difference between selective and nonselective inhibitors with respect to central 5-HT release, is the excitatory effect of (alpha 1) adrenergic receptor stimulation on 5-HT neuronal discharge. However, pretreatment with alpha-methyl-p-tyrosine to deplete NA, did not influence the inhibition of 5-HT release produced by imipramine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623967     DOI: 10.1016/0028-3908(94)00137-h

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences.

Authors:  Nicolas Narboux-Nême; Corinne Sagné; Stephane Doly; Silvina L Diaz; Cédric B P Martin; Gaelle Angenard; Marie-Pascale Martres; Bruno Giros; Michel Hamon; Laurence Lanfumey; Patricia Gaspar; Raymond Mongeau
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

2.  Possible in vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats.

Authors:  M B Assié; W Koek
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Differential regulation of 5-hydroxytryptamine release by GABAA and GABAB receptors in midbrain raphe nuclei and forebrain of rats.

Authors:  R Tao; Z Ma; S B Auerbach
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

4.  Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo.

Authors:  S B Auerbach; S Hjorth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

5.  Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.

Authors:  Tracy M Felton; Tommy B Kang; Stephan Hjorth; Sidney B Auerbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-04       Impact factor: 3.000

6.  The effect of clomipramine on wake/sleep and orexinergic expression in rats.

Authors:  P Feng; Y Hu; D Li; D Vurbic; H Fan; S Wang; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

Review 7.  The use of serotonergic drugs to treat obesity--is there any hope?

Authors:  Nicholas T Bello; Nu-Chu Liang
Journal:  Drug Des Devel Ther       Date:  2011-02-10       Impact factor: 4.162

8.  Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT1A [11C]CUMI-101 PET and Functional MRI Study.

Authors:  Sudhakar Selvaraj; Chris Walker; Danilo Arnone; Bo Cao; Paul Faulkner; Philip J Cowen; Jonathan P Roiser; Oliver Howes
Journal:  Neuropsychopharmacology       Date:  2017-08-04       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.